You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海正藥業(600267.SH):擬通過自主研發以及外部合作方式引入第一批合成生物產業化項目
格隆匯 12-27 17:14

格隆匯12月27日丨海正藥業(600267.SH)公佈,鑑於合成生物學市場需求的良好潛能和公司戰略佈局,基於公司在生物製造領域明顯的產業技術轉化和產能優勢,公司通過自主研發以及外部合作方式引入第一批合成生物產業化項目,為加快合成生物學產業項目落地,提高公司資產利用率,同意公司利用巖頭東外區現有廠房,採用先進技術裝備對提取、公用系統等車間進行技術改造,建成先進的專業化合成生物學產品柔性生產線。項目改造範圍為Y27、Y108、Y109、Y110、Y112號廠房,上述廠房建築物佔地面積11,951平方米,建築面積約36,849平方米。項目計劃總投資17,106.04萬元,其中建設投資15,397.59萬元,建設期資金籌措費194.01萬元,鋪底流動資金1,514.44萬元。根據測算,項目建成投產後,預計實現年均銷售收入約41,579.03萬元,總投資收益率19.67%,靜態投資回收期5.96年,項目具有較好的盈利能力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account